Building on new research about senescent cell behaviour, several biotech firms announced that their precision senolytics have entered Phase 2 clinical trials in elderly patients. Senolytics aim to clear so-called zombie cells that accumulate with age and secrete inflammatory factors linked to tissue decline.
Phase 2 studies will evaluate safety, dosing, and preliminary efficacy signals across age-related conditions including frailty and osteoarthritis. Regulators require robust adverse-event tracking because systemic cell clearance could affect wound healing and immune surveillance.
Earlier laboratory work suggested selective elimination of senescent cells can rejuvenate certain tissues in animal models. Translating those results to humans remains uncertain given biological complexity and comorbidities common in older trial participants.
Investors are monitoring readouts that could influence the broader anti-ageing therapeutics market. Ethicists urge transparent consent processes so participants understand experimental status and unknown long-term effects.
Successful trials would mark a milestone for therapies targeting fundamental ageing mechanisms rather than individual late-stage diseases alone.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/